About olipudase alfa
Recombinant acid sphingomyelinase enzyme replacement
Used for
- Treats non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD), types A/B and B.
Usual adult dose
Gradually increased to 3 mg/kg by intravenous infusion every two weeks.
Usual dose in children
Gradually increased to 3 mg/kg by intravenous infusion every two weeks; dosing depends on age and weight.
Common side effects
- Headache, fever, nausea, and abdominal pain
- Infusion reactions, including rash, itching, or breathing difficulty
- Increased liver enzymes
- Severe allergic reactions, including anaphylaxis
Important warnings
- Infusion reactions can be serious; treatment requires monitoring during and after infusions.
- Liver enzyme increases may occur, especially during dose escalation.
- Not expected to treat central nervous system symptoms.
- Doses are increased gradually under specialist supervision.
Pregnancy
Human pregnancy data are limited; use requires weighing potential benefits and risks.
Breastfeeding
It is unknown whether olipudase alfa passes into breast milk; clinical data are limited.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.